Molecular Partners AG · SIX:MOLN
Molecular Partners — Investor Day (December 2020)
90 slides from Molecular Partners's investor day presentation, Dec 17, 2020
Slide 1: Unlock and Expand: Custom Built Biology for Patients
Unlock and Expand: Custom Built Biology for Patients R&D Day 2020 Molecular Partners AG, Switzerland (SIX: MOLN) 1
Slide 2: Disclaimer
Disclaimer This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. T
Slide 3: R&D Day Speakers
R&D Day Speakers Patrick Amstutz, PhD Lutz Hegemann, MD, PhD Chief Executive Officer, Molecular Chief Operating Officer, Global Health, Partners Novartis Mario Sznol, MD Professor of Medicine (Medical Nicolas Leupin, MD Oncology) / Co-Leader, Cancer Chief Medical Officer, Molecular Partners Immunolo
Slide 4: Pioneering DARPin Therapies to Transform Lives
Pioneering DARPin® Therapies to Transform Lives Overview: Patrick Amstutz 4
Slide 5: Pioneering DARPin Solutions
Pioneering DARPin® Solutions We aim to transform the We translate the unique We build a broad lives of people with properties of the pipeline of DARPin® serious diseases by DARPin® drug class therapeutics to address delivering truly innovative into patient value unmet medical need solutions our purp
Slide 6: Highlights 2020
Highlights 2020 Opportunity Execution Recognition • First & only multi-specific • Expanded development and • Increased cash on balance COVID drug in clinical research pipelines despite sheet by over $155m in 2020 development (ensovibep) lock-down • Raised $90m • Idea to candidate in 12 weeks • Advan
Slide 7: Innate Advantages Combined With Proprietary Approaches
Innate Advantages Combined With Proprietary Approaches Unique DARPin® Features DARPin® Benefit Tailored Grip • Match disease requirements Ideal binding properties • Perfect fit • High affinity • Super specificity Localized Activity • Local and temporal control of activity Turn-key multi-specifics •
Slide 8: A Portfolio Strategy Delivering Growth And Innovation
A Portfolio Strategy Delivering Growth And Innovation Ophthalm- Oncology Virology ology Abicipar MP0250 MP0274 MP0310 MP0317 CD-3 pMHCs MP0420 MP0423 Preclinical & Localized activity Discovery Phase 1 Tailored molecular grip Phase 2 Escape prevention Phase 3 Molecular handcuffs 8
Slide 9: Establishing the Platforms with First-Generation Programs
Establishing the Platforms with First-Generation Programs Abicipar MP0250 MP0274 • Two positive clinical trials • Biological activity in combination • Biological activity in a patient (CEDAR & SEQUOIA) with Velcade in multiple myeloma • Principle of molecular • June 2020: CRL received • Principle of
Slide 10: Synergistic Partnerships Built on a Versatile Drug Class
Synergistic Partnerships Built on a Versatile Drug Class Ophthalmology Oncology Virology Therapeutic Area Deal Product Combination Deal Capability Deal • Partnership for abicipar, two • Partnership with Amgen to • Leverage production, global positive Phase 3 studies. combine AMG 506 / MP0310 develop
Slide 11: COVID-19 Program Success Opens Path for Antiviral Portfolio
COVID-19 Program Success Opens Path for Antiviral Portfolio Overview: Patrick Amstutz Global context: Lutz Hegemann, MD, Ph.D. 11
Slide 12: Global Pandemics Underscore Major Therapeutic Needs
Global Pandemics Underscore Major Therapeutic Needs The requirements to reopen the world is a cooperative action between: • Efficacious vaccines with swift uptake Vaccines • Responsible global citizens • Effective and available antiviral Hygiene/ therapies to prevent outbreaks, and to social protect
Slide 13: Antibody Mixtures Are Sub-optimal Antivirals
Antibody Mixtures Are Sub-optimal Antivirals Antibody Antibody mixture mixture Monoclonal antibody drawbacks however ✓ Effective X High cost X Limited amounts 13
Slide 14: One molecule to do the work of several
One molecule to do the work of several Antibody Cocktail A single DARPin® with multi-specific binding 14
Slide 15: Our COVID-19 Program: Two Outstanding Candidates
Our COVID-19 Program: Two Outstanding Candidates MP0420 (ensovibep)– best-in-class MP0423 – first-in-class • Tri-specific DARPin® antiviral targeting the RBD for • 3 DARPins blocking different domains of the viral spike highest potency & to prevent viral escape • High activity even if RBD mutates he
Slide 16: Cooperative Target Engagement Leads To Super Affinity
Cooperative Target Engagement Leads To Super Affinity DARPin #1; 1 hour off-rate DARPin #2; 1 hour off-rate DARPin #3; 1 hour off-rate Response (RU) Response (RU) Response (RU) Time (s) Time (s) Time (s) Response (RU) Multi-DARPin #1 - #2 - #3 sub pM target binding Time (s) 16
Slide 17: High Potency Inhibition Translates To In Vivo Properties
High Potency Inhibition Translates To In Vivo Prophylactic And Therapeutic Properties In vitro activity: Pseudotype In vivo activity: Kaplan Meier Plot - Neutralization Assay Hamster Model Pseudotype Neutralization Assay 100 1 Probability of MP0420, MP0423 Infection [%] Survival 50 MP0420 Placebo IC
Slide 18: Ensovibep Blocks the Virus and Prevents Infection in the Lung
Genome Copi Genome Copi 10 4 10 4 Ensovibep Blocks the Virus and Prevents Infection in the 10 3 10 2 10 3 10 2 Lung 10 1 10 0 10 1 10 0 qPCR - lung Day 3 qPCR - lung Day 5 Red symbols: animals taken out of the study (at day 2 and 3) due to Viral 10 titer in the lung 8 Viral infectivity in the lung s
Slide 19: MP0420 (ensovibep) Phase 1 Ongoing
MP0420 (ensovibep) Phase 1 Ongoing • Study initiated November 2020, first cohort fully enrolled • Double-blind, placebo controlled trial exploring safety and PK. • IV administration • Up to 24 subjects total, stratified 3:1 (active: placebo) • Ages 18-65 • Dose range include 3 mg/kg (225 mg*), 9 mg/
Slide 20: Novartis Collaboration Highlights Strengths of Each Company
Novartis Collaboration Highlights Strengths of Each Company Both parties commit to Novartis: global access, aiming to manufacturing, supply and make candidates available logistics for global reach to all countries in need A common sense of principles, purpose, and urgency Molecular Partners: Novarti
Slide 21: Novartis COVID-19 response
Novartis Global Health Novartis COVID-19 response Molecular Partners R&D Day 17 December 2020 Dr Lutz Hegemann COO, Global Health, Novartis
Slide 22: Our response to COVID-19 pandemic
Our response to COVID-19 pandemic Safety Ensuring safety and wellbeing of our associates Demonstrating resilience in our core operations Resilience (e.g. supply chain, clinical trials, HCP interactions, etc.) Supporting global pandemic response Response Financial aid and donations, repurposing of ex
Slide 23: An integrated approach will be required
An integrated approach will be required Mandatory to reach an epidemiological end to the pandemic. Vaccines However are not a “silver bullet’ and will require continued therapeutic reinforcements Fundamental in outbreak and case management, allowing Diagnostics rapid identification to respond to pat
Slide 24: Desired characteristics of a COVID-19 therapeutic
Desired characteristics of a COVID-19 therapeutic ▪ Can be used at different stages of the disease and in early, pre-symptomatic, high risk groups ▪ High potency for anti-viral effect in therapeutic setting ▪ Ease of administration ▪ Multi-epitope targeting to prevent escape mutations ▪ Ability to s
Slide 25: Draft Development plan for MP0420
Draft Development plan for MP0420 ALL DATES PRELIMINARY, SUBJECT TO HEALTH AUTHORITY INPUT 2020 2021 2022 Possible EUA* BLA Ph.1 studies Phase 2/3 part A (N 400-700) Phase 2/3 Part B (N >2000) Submission Clinical (healthy volunteers, Development Covid +ve patients) Additional supporting studies for
Slide 26: Thank you
Tek Cat ev AYYAYYAYAY VAY Vader Cr a eg ar as AT Teeny RA aT Tt rEAT cat Tr ATYATYATAY TVA TA ye ger Tae Tek Tt SGU pn ou a OT LT AT A LEAT TAME TT ee ese fs SAL ie ta 2 EY TT eV CA Yn Le er LT TCL TCL TT LCT ATTA AT AT a et 2a ST ey, mEAY ean ey, ae See ae os TAT VALET LETT ANALY YrAYrayryy teu g u
Slide 27: Our Antiviral Portfolio Vision
Our Antiviral Portfolio Vision: Broaden the use and recognition of DARPin® Antivirals Continue toward POC in COVID in 2021 - Unlock Clear need and capability of developing multi-specific DARPin antivirals - Expand Pipeline analysis underway to evaluate viral opportunities of greatest unmet therapeut
Slide 28: Clinical Programs: Expanded
Clinical Programs: Expanded Nicolas Leupin, MD, MBA 28
Slide 29: One Year in Review, the Take Home Messages
One Year in Review, the Take Home Messages 1. DARPins continue to deliver on clinical design 2. We are becoming very efficient at translating an idea and implementing it into the clinic 3. The path to big discoveries and breakthroughs is never easy - whether it’s success or failure 29
Slide 30: DARPins Continue to Deliver on Clinical Design
DARPins Continue to Deliver on Clinical Design 45 year old woman, 9 doses of MP0274, achieving partial response (Dec 2020) 2012 initial diagnosis Breast cancer, stage IV 2012 to 2020 Several lines of anti cancer treatment containing Trastuzumab Jun 2020 First dose MP0274 (12mg/kg), still ongoing Bas
Slide 31: Unlock and Expand: Therapeutic Platforms
Unlock and Expand: Therapeutic Platforms Targeting peptide MHC complexes Next-generation T-cell engagers Unlock therapeutic platforms Tumor-localized immune cell activation Expand application space 31
Slide 32: Application: Local T Cell Targeted Activation
Application: Local T Cell Targeted Activation Traditional CAR-T “CAR-T in situ” Tumor stromal cell T cell FAP 4-1BB activation MP0310 CD3 Tumor targeting Tumor cell T cell engager Tumor cell 32
Slide 33: Unlock: Local Activation of Immune cells: FAP as a General Switch
Unlock: Local Activation of Immune cells: Fibroblast Activation Protein (FAP) as a General Switch BODY TUMOR • In normal tissues, receptor is • High FAP concentration near broadly distributed tumor clusters receptors • Immune cell remains inactive • Immune cell is activated 4-1BB or CD40 VS Tumor st
Slide 34: AMG 506 / MP0310 and 4-1BB Biology
AMG 506 / MP0310 and 4-1BB Biology 34
Slide 35: 4-1BB – A Potent Co-stimulatory Molecule of TNFR Family
4-1BB – A Potent Co-stimulatory Molecule of TNFR Family DC +Antigen presentation, FAP expression adequate for immune B7-1/B7-2, IDO, IL-12, IL-27 activation in multiple solid tumors Macrophage +IDO, IL-8 NK Cell +ADCC, +IFNy Treg Cells α4-1BB Suppression, Expansion, Polarization CD8+ T Cells +Cytoto
Slide 36: Clinical Plan for AMG 506 / MP0310
Clinical Plan for AMG 506 / MP0310 Single-Agent Optimized dose Dose Escalation schedule Leads to Combo Dose Escalation(s) P2 & P3
Slide 37: AMG 506 / MP0310 Dose Escalation Completed
AMG 506 / MP0310 Dose Escalation Completed • Executed on schedule through 2020 AESI N affected pts. / Max. N events grade Infusion related reactions > G 1* 12 / 19 3 • 22 patients enrolled, 19 presently evaluable Cytokine release syndrome – any 0 - Hepatitis – any 0 - • 7 dosing cohorts Pneumonitis
Slide 38: Combination of AMG 506 / MP0310 and TAA x CD3 Increases CD8+ T Cells
Combination of AMG 506 / MP0310 and TAA x CD3 Bi-Specific Results in Significant Increase of Intratumoral CD8+ T Cells FAP-Mediated Tumor Intratumoral CD8 T cells Accumulation of AMG 506 HT-29-T-implanted NSG mice TAA x CD3 Tumor + AMG 506 TAA x CD3 + mFAP x 4-1BB no-FAP x 4-1BB mFAP x 4-1BB 38
Slide 39: AMG 506 / MP0310 Accumulates in Tumor Tissue in Dose Dependent Manner
AMG 506 / MP0310 Accumulates in Tumor Tissue in Dose Dependent Manner MP0310 (0.5mg/kg) colocalizes with FAP MP0310 (5mg/kg) saturates FAP MP0310 < FAP MP0310 > FAP FAP+ Stroma rich area Endometrial carcinoma (Liver metastasis), C1D15 NSCLC (lung), C1D15 39
Slide 40: AMG 506 / MP0310 Does not Activate T and NK Cells Off-Target
AMG 506 / MP0310 Does not Activate T and NK Cells Off- Target Q3W C1D1 C1D8 C2D1 C2D8 C4D1 FU IPT EOT (Fresh Blood Sample) MP0310 Note: C1D1, C2D1, C4D1 – Predose sample EOT: end of treatment, FU: follow up sample No significant changes over time in immune cell subsets in periphery Immune cell subse
Slide 41: AMG 506 / MP0310 Dose Escalation Completed
Cohort Patient ID Cancer type Cycles Best Response AMG 506 / MP0310 Dose Escalation 1 0.015mg/kg 03-001 03-002 Mesothelioma Cutaneous squamous cell 4 5 SD SD Completed 03-003 Mesothelioma 4 SD 2 02-001 Ovarian adenocc 4 PD 0.05mg/kg 01-001 Pancreatic adenocc 3 SD 03-004 Pancreatic adenocc 2 PD • 22
Slide 42: PD Activity in Paired Biopsies Supports MoA on 4-1BB Activation
PD Activity in Paired Biopsies Supports AMG 506 / MP0310 MoA on 4-1BB Activation CD8 T Cells Cytotoxicity IFN Gamma NK Cells T Cells TH1 Cells 6 Signature score (log2) 5 CD4 NK Cell +IFNy +IFNy +Proliferation 4 3 CD8 +Cytotoxicity +IFNy/TNF⍺ +Proliferation 2 ↑ T and NK population Time point ↑ IFNγ a
Slide 43: AMG 506 / MP0310 – Key messages, Biomarkers
AMG 506 / MP0310 – Key messages, Biomarkers Target occupancy PD activity • Tumor (mIF) • Tumor (Gene expression): • MP0310 in tumor tissue observed first time in • Significant immune activation across multiple cohort 4 (0.5mg/kg) and colocalizes with FAP immune cells as expected by MoA for • MP0310
Slide 44: AMG 506 / MP0310 – Key Messages
AMG 506 / MP0310 – Key Messages 1. Good safety profile without major systemic toxicity a. No liver toxicity, no systemic activation of immune cells b. IRRs frequent but manageable 2. MP0310 is observed in tumor tissue 3. Tumor biopsies show tumor-localized immune response consistent with the MoA of
Slide 45: MP0317 and CD40 Biology
MP0317 and CD40 Biology 45
Slide 46: MP0317: Localized Activation of CD40
MP0317: Localized Activation of CD40 Half-life FAP CD40 Immune Extender Localizer Modulators (2) ➢ CD40 serves pivotal role in the immune response via interactions between T cells and antigen-presenting cells ➢ Novel mode of action: Localized activation of CD40 in a FAP dependent manner, potentially
Slide 47: Development of CD40 agonists
Development of CD40 agonists Mario Sznol, MD Professor of Medicine (Medical Oncology) / Co- Leader, Cancer Immunology, Yale Cancer Center / Co-Director, Yale SPORE in Skin Cancer 47
Slide 48: Disclaimer and Experience with CD40 pathway
Disclaimer and Experience with CD40 pathway • Consultant for Molecular Partners • Consultant for other companies developing CD40 agonists • Personal clinical experience with APX005M 48
Slide 49: Improving Anti-tumor Immunity
Improving Anti-tumor Immunity - Non- Immunogenic immunogenic Increase tumors tumors breadth Retain T-cell - Lost T-cell of T-cell Enhance tumor recognition recognition response cell sensitivity Increase to immune magnitude effector killing of response Innate immunity CAR-T cell + chemotherapy Block
Slide 50: Agonistic CD40 Antibodies and Cancer Therapy
Agonistic CD40 Antibodies and Cancer Therapy CD40 present on subset of APC, myeloid cells, B cells, some tumor cells, platelets, fibroblasts, and endothelial cells. Clin Cancer Res; 19(5); 1035–43. 2013 AACR. 50
Slide 51: Agonist CD40 may address major mechanisms of resistance
Agonist CD40 may address major mechanisms of resistance CD40 agonist Innate immunity on macrophages Increase phagocytosis + chemotherapy Alter tumor promoting properties + targeted molecular therapies + anti-angiogenesis CD40 agonist on dendritic • Increase breadth Increase MHC expression cells/anti
Slide 52: Antibody Agonist CD40 Agents in Development
Antibody Agonist CD40 Agents in Development • CP-870,893/RO7009789 • APX005M • ADC-1013 • Chi Lob 7/4 • SEA-CD40 • CDX-1140 Exclusive of bispecifics 52
Slide 53: Summary of Clinical Data
Summary of Clinical Data • Low MTD • Relatively short half-life • Tolerable adverse events including limited CRS, mild thrombocytopenia, and LFT elevations • Single agent activity in melanoma • Activity (+ anti-PD-1) in anti-PD-1 resistant melanoma • Promising combination activity with gemcitabine a
Slide 54: CD40 Target - Opportunities and Challenges
CD40 Target - Opportunities and Challenges • Large in vivo sink + low MTD • potential to increase activation within tumor with novel tumor targeted approaches • Critical/non-redundant target for a subset of patients • but may still require combinations for optimal anti-tumor activity • Promising com
Slide 55: CD40 requires clustering for activation
CD40 requires clustering for activation • Efficient signaling through CD40 requires high level of cross-linking • Our solution: a FAP x CD40 bispecific molecule binding a densely expressed tumor associated antigen for clustering 55
Slide 56: MP0317: FAP-dependent Activation of Specific Immune Cells
MP0317: FAP-dependent Activation of Specific Immune Cells A B C Dendritic cells: Macrophages: B cells: CD86 ✓ IL-12 ✓ TNFα ✓ IL-12 ✓ CD69 ✓ CD83 ✓ CD80 ✓ IL-6 ✓ CCL17 ✓ CD86 ✓ x10 MP0317 in presence of FAP MP0317 in presence of FAP MP0317 in presence of FAP 3 MP0317 in absence of FAP MP0317 in absen
Slide 57: MP0317 Shows Full Activity with No Detectable Side-effects
MP0317 Shows Full Activity with No Detectable Side-effects FAPHIGH TUMOR: MC38-FAP Colorectal cancer Vehicle Neg. CTRL* Tumor growth (mm3) mFAP x mCD40 mCD40 Ab Time after tumor inoculation (days) 57
Slide 58: MP0317 – Key messages
MP0317 – Key messages CD40 Biology • Highly promising target with potential to significantly impact clinical outcomes for patients • Difficult biology to manage, and administer safely and efficaciously MP0317 Clinical Plans • FAP localization translating well, and will provide insights into dosing s
Slide 59: New Therapeutic Platforms: Unlocked
New Therapeutic Platforms: Unlocked Daniel Steiner, PhD 59
Slide 60: From DARPin Features to Benefits
From DARPin® Features to Benefits DARPin® Facts Unique DARPin® Features DARPin® Benefit • Turn-key Multispecifics: multi- • Disease-localized activity to DARPin® formatting with up to open the therapeutic window 7 functionalities in one molecule • Multi-blocker to prevent • Small (15 kDa) and simple
Slide 61: Unlock and Expand: Therapeutic Platforms
Unlock and Expand: Therapeutic Platforms Targeting peptide MHC complexes Next-generation T-cell engagers Unlock therapeutic platforms Tumor-localized immune cell activation Expand application space 61
Slide 62: Unlock and Expand: Therapeutic Platforms
Unlock and Expand: Therapeutic Platforms Targeting peptide MHC complexes Next-generation T-cell engagers Unlock therapeutic platforms Tumor-localized immune cell activation Expand application space 62
Slide 63: Challenges of T-cell Engagers in the Clinic
Challenges of T-cell Engagers in the Clinic Safety Efficacy TOXICITY PROFILE LIMITS OPTIMAL DOSING LACKING LONG-LASTING AND DEEP RESPONSES Tumor escape & relapse Attack on healthy tissues (heterogeneity, target loss, (on-target off-tumor binding) mutation or downregulation) Current T-cell Engagers H
Slide 64: Multi-specific DARPin T-cell Engager with Improved Benefit/Risk in AML
Multi-specific DARPin® T-cell Engager with Improved Benefit/Risk in AML Medical problem • High medical need and high relapse rate in AML with current therapies • Single-target T-cell engagers show promising efficacy, but optimal biological dose level not reached due to dose-limiting toxicities DARPi
Slide 65: Multi-DARPin Versatility Allows Screening for Function Sweet Spot
Multi-DARPin® Versatility Allows Screening for Function Sweet Spot # molecules Multi-domain DARPin® space Library to generate binders 1012 against TAA1 / TAA2 / TAA3… Identified functional and well behaved 10s DARPin® modules (for each target) Sweet X X spot Recombination of DARPin® modules: CD3 TAA
Slide 66: Multi-DARPins for AML Show High Potency, Improved Selectivity
Multi-DARPins® for AML Show High Potency, Improved Selectivity and Potential for Reduced CRS In-vitro potency and specificity 100000 Ex-vivo cytokine release in 100000 assessment on AML cells healthy human whole blood TNF (pg/ml) TNF (pg/ml) 10000 10000 100x100x TAA1TAA1 x TAA2 x TAA2 10001000 1x
Slide 67: Expand with Platform for Controlled Activation of CD3 Effector Function
Expand with Platform for Controlled Activation of CD3 Effector Function Where Inactive at When Conditional activation locally in the TME treatment start Slow activation over time in circulation Tumor anti- CD3 Concentration cell Conventional TCE dosage Controlled release anti- CD3 Time • Local activ
Slide 68: DARPin solutions for improved benefit-risk profile of T-Cell Engagers
DARPin® solutions for improved benefit-risk profile of T-Cell Engagers Safety Efficacy DECREASED TOXICITY FOR OPTIMAL DOSING LONG-LASTING AND DEEP RESPONSES Decreased attack on healthy Circumvent tumor escape & tissues relapse Robust CD3 Toolbox (spanning the entire CD3 binding spectrum, PK, develop
Slide 69: DARPin solutions for improved benefit-risk profile of T-Cell Engagers
DARPin® solutions for improved benefit-risk profile of T-Cell Engagers Safety Efficacy DECREASED TOXICITY FOR OPTIMAL DOSING LONG-LASTING AND DEEP RESPONSES Multi-specific T-cell Engagers Multi-specific T-cell Engagers to with increased selectivity cover heterogeneous tumors Decreased attack on heal
Slide 70: DARPin solutions for improved benefit-risk profile of T-Cell Engagers
DARPin® solutions for improved benefit-risk profile of T-Cell Engagers Safety Efficacy DECREASED TOXICITY FOR OPTIMAL DOSING LONG-LASTING AND DEEP RESPONSES Multi-specific T-cell Engagers Multi-specific T-cell Engagers to with increased selectivity cover heterogeneous tumors Decreased attack on heal
Slide 71: DARPin solutions for improved benefit-risk profile of T-Cell Engagers
DARPin® solutions for improved benefit-risk profile of T-Cell Engagers Safety Efficacy DECREASED TOXICITY FOR OPTIMAL DOSING LONG-LASTING AND DEEP RESPONSES Multi-specific T-cell Engagers Multi-specific T-cell Engagers to with increased selectivity cover heterogeneous tumors Decreased attack on heal
Slide 72: DARPin solutions for improved benefit-risk profile of T-Cell Engagers
DARPin® solutions for improved benefit-risk profile of T-Cell Engagers Safety Efficacy DECREASED TOXICITY FOR OPTIMAL DOSING LONG-LASTING AND DEEP RESPONSES Multi-specific T-cell Engagers Multi-specific T-cell Engagers to with increased selectivity cover heterogeneous tumors Decreased attack on heal
Slide 73: Unlock and Expand: Therapeutic Platforms
Unlock and Expand: Therapeutic Platforms Targeting peptide MHC complexes Next-generation T-cell engagers Unlock therapeutic platforms Tumor-localized immune cell activation Expand application space 73
Slide 74: Peptide MHC Complexes: Inaccessible Intracellular Targets
Peptide MHC Complexes: “Inaccessible” Intracellular Targets Tumor Surface Antigens Challenges of the pMHC redirected T-Cell engager field: • Generation of binders with high selectivity and high potency • High investment to generate binders • Systemic half-life extension often leads Intra-cellular ta
Slide 75: Multiple Technical pMHC Challenges: Solved
Multiple Technical pMHC Challenges: Solved Gained several logs of potency Achieved good systemic exposure Candidate production for several pMHCs while maintaining selectivity IM9 (Ag+) x=L with limited impact on potency in parallel in less than six months IM9 (Ag+ ) x=M IM9 (Ag+ ) x=S pMHC x CD3 x H
Slide 76: DARPin Platform Especially well Suited to Address pMHC Targets
DARPin® Platform Especially well Suited to Address pMHC Targets Effector: DARPin® CD3 binder Binders with high specificity and high potency Rapid and reliable generation of pMHC binders DARPin® - Systemic half-life extension with limited impact on pMHC binder potency Good developability properties P
Slide 77: DARPin Opportunities in Virology
DARPin® Opportunities in Virology Respiratory • RSV, influenza and others Viruses • Benefits as per COVID DARPin® • Multi-valency for superior potency • Corona, influenza Pandemic readiness • Early intervention • Multi-specificity for mutation to prevent spread resistance COVID • Speed of candidate
Slide 78: Summary and Outlook Into 2021
Summary and Outlook Into 2021 Targeting peptide MHC complexes Next-generation T-cell engagers Unlock Virology therapeutic platforms Tumor-localized immune cell activation Expand application space 78
Slide 79: Summary and Outlook Into 2021
Summary and Outlook Into 2021 Targeting peptide MHC complexes Next-generation T-cell engagers Unlock Virology therapeutic platforms DARPin building blocks ready to expand Tumor-localized immune tumor-localized immune cell activators cell activation based on strong clinical data of MP0310/317 Expand
Slide 80: Summary and Outlook Into 2021
Summary and Outlook Into 2021 Targeting peptide MHC complexes Progressing multi-specific T-cell Engager Next-generation candidates and expanding first product T-cell engagers candidates with "controlled activation" Unlock Virology therapeutic platforms DARPin building blocks ready to expand Tumor-lo
Slide 81: Summary and Outlook Into 2021
Summary and Outlook Into 2021 Solid pMHC DARPin® platform Targeting peptide established: progressing candidates MHC complexes internally and in partnerships Progressing multi-specific T-cell Engager Next-generation candidates and expanding first product T-cell engagers candidates with "controlled ac
Slide 82: Summary and Outlook Into 2021
Summary and Outlook Into 2021 Solid pMHC DARPin® platform Targeting peptide established: progressing candidates MHC complexes internally and in partnerships Progressing multi-specific T-cell Engager Next-generation candidates and expanding first product T-cell engagers candidates with "controlled ac
Slide 83: Conclusions
Conclusions Patrick Amstutz Confidential Confidential 83
Slide 84: Summary
Summary • DARPins show clinical activity • CD40 biology is relevant and needs solutions • New team well in place • Mechanism allows for multiple combination • MP0310 – strong evidence of activity opportunities • MP0317 – FIH 2021 • Dosing and administration are key to activity • Therapeutic Platform
Slide 85: Financial Overview & Milestones
Financial Overview & Milestones: • Cash 30 November, 2020: ~$200m, no debt • Expense guidance for FY2020: CHF 65-75m • Successful capital raise of CHF 80m, completed in early July 2020 • Additional funding from Novartis transaction (CHF 60m, received per end October 2020) • Funded into 2023, without
Slide 86: Upcoming Catalysts Across The Portfolio in 2021
Upcoming Catalysts Across The Portfolio in 2021 Antiviral portfolio MP0420 ▪ POC with EUA/BLA and approval in 2021 (ensovibep) ▪ Emergency Use Authorization and/or BLA submission possible in 2021 MP0423 ▪ MP0423 FIH Novel antivirals ▪ Develop novel DARPins for viral targets with first new target ann
Slide 87: Upcoming Catalysts Across The Portfolio in 2021
Upcoming Catalysts Across The Portfolio in 2021 Antiviral portfolio MP0420 ▪ POC with EUA/BLA and approval in 2021 (ensovibep) POC for ▪ Emergency Use Authorization and/or BLA submission possible in 2021 MP0423 MP0420 ▪ MP0423 FIH Novel antivirals ▪ Develop novel DARPins for viral targets with first
Slide 88: Live, Love, Laugh
Live, Love, Laugh MOLECULAR . Gtters MOLECULAR partners 88
Slide 89: Safe and happy holidays to everyone
Safe and happy holidays to everyone 89
Slide 90: Molecular Partners AG
Molecular Partners AG Wagistrasse 14 8952 Zürich-Schlieren Switzerland www.molecularpartners.com T +41 44 755 77 00 90